---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-009955"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T22:21:17.671294+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# FDA removes Boxed Warning for testosterone products after TRAVERSE trial benefits Lipocine

## Summary
- FDA removes Boxed Warning on cardiovascular risk for all testosterone products based on TRAVERSE trial.
- Label changes include adding TRAVERSE results and retaining Limitation of Use for age-related hypogonadism.
- FDA requires product-specific blood pressure information from ABPM studies on all testosterone labels.
- Lipocine CEO says label changes beneficial to approved TLANDO and pipeline candidates for obesity and liver disease.

## SEC filing metadata
- accession: 0001493152-25-009955
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315225009955/0001493152-25-009955-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315225009955/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-009955
- JSON: https://secwatch.observer/filing/0001493152-25-009955.json
- Plain text: https://secwatch.observer/filing/0001493152-25-009955.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.